Integral Health Asset Management LLC Boosts Position in Astrazeneca Plc $AZN

Integral Health Asset Management LLC raised its position in Astrazeneca Plc (NYSE:AZN) by 50.0% during the 3rd quarter, Holdings Channel reports. The firm owned 300,000 shares of the company’s stock after acquiring an additional 100,000 shares during the quarter. Astrazeneca comprises about 1.6% of Integral Health Asset Management LLC’s holdings, making the stock its 15th biggest position. Integral Health Asset Management LLC’s holdings in Astrazeneca were worth $23,016,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Cibc World Market Inc. raised its position in Astrazeneca by 21.5% during the third quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock worth $4,942,000 after acquiring an additional 11,398 shares during the last quarter. TD Asset Management Inc grew its position in shares of Astrazeneca by 20.0% in the third quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock valued at $83,595,000 after purchasing an additional 181,273 shares during the last quarter. Y Intercept Hong Kong Ltd grew its position in shares of Astrazeneca by 111.6% in the third quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company’s stock valued at $5,113,000 after purchasing an additional 35,148 shares during the last quarter. AMG National Trust Bank increased its stake in shares of Astrazeneca by 20.4% during the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock worth $3,298,000 after purchasing an additional 7,289 shares in the last quarter. Finally, Oxbow Advisors LLC increased its stake in shares of Astrazeneca by 96.2% during the 3rd quarter. Oxbow Advisors LLC now owns 77,594 shares of the company’s stock worth $5,953,000 after purchasing an additional 38,043 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on AZN. Wall Street Zen lowered Astrazeneca from a “buy” rating to a “hold” rating in a research note on Thursday. Guggenheim reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, December 3rd. Citigroup began coverage on Astrazeneca in a report on Tuesday, January 27th. They issued a “buy” rating for the company. Weiss Ratings initiated coverage on Astrazeneca in a research report on Wednesday. They issued a “buy (b)” rating on the stock. Finally, TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Tuesday, December 9th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $95.75.

Astrazeneca Price Performance

NYSE:AZN opened at $190.20 on Friday. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $294.98 billion, a PE ratio of 29.04, a PEG ratio of 1.45 and a beta of 0.32. Astrazeneca Plc has a 1-year low of $122.48 and a 1-year high of $212.71.

Astrazeneca Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be issued a dividend of $1.595 per share. The ex-dividend date is Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca’s dividend payout ratio (DPR) is 66.26%.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.